News
Chameleon Biosciences Presents Poster on AAV Gene Therapy Redosing Success at ESGCT
The European Society of Gene & Cell Therapy (ESGCT) Welcomes Chameleon’s Animal Study Results Poster at its 29th Annual Conference in Edinburgh, U.K.
> Read More
Chameleon Founder Speaks at 2nd annual Gene Therapy Next Generation Vector Summit
CEO and scientist, Genine Winslow, presents Immune Suppressive AAV Based Gene Therapy for Repeat Dosing at annual event dedicated to overcoming the current immunogenicity, toxicity and manufacturability challenges facing the field by pioneering the next generation of superior delivery vectors.
> Read More
Chameleon Biosciences welcomes Alan Belicha, Ph.D.
We are pleased to announce and welcome Alan Belicha to the Chameleon team as Vice President of Business Development. In this role, Alan will guide Chameleon’s corporate development and partnering strategy, and contribute to financing efforts. We are excited to have Alan’s experience from the University of Buffalo, Mount Sinai Innovation Partners, and TTO Consulting Strategic available to our team,…
> Read More
Chameleon Founder Speaks at 5th annual Gene Therapy for Rare Disorders Conference
Immunology and gene therapy CEO and scientist, Genine Winslow, presents innovative vector modifications at industry summit. Learn more about the conference and see the press release.
> Read MorePress Releases
- July 19, 2022
EIN Presswire: Chameleon Founder Speaks at 2nd annual Gene Therapy Next Generation Vector Summit /
CEO and scientist presents Immune Suppressive AAV Based Gene Therapy for Repeat Dosing - April 29, 2022
EIN Presswire, MENAFN
Science News Today: CEO/CFO Interviews Chameleon Biosciences, Inc. Founder CEO, Genine Winslow on how they are Expanding AAV Gene Therapies with EVADER™ - March 9, 2022
AP News, Benzinga, Yahoo! Finance:
Chameleon Biosciences Founder to Speak at Gene Therapy Next Generation Vector Summit 2022 in Boston - Jan 5, 2022
AP News, Big News Network, Digital Journal, Yahoo! Finance:
Chameleon Biosciences Appoints Silicon Valley Scientist and Entrepreneur, Dr. Thomas Chalberg, to Board Position
What Others Are Saying...
- Nov 8, 2022
BioPharma Reporter:
Chameleon's immunomodulatory technology wins biotech breakthrough award - May 9, 2022
Cell and Gene Therapy Insights:
Overcoming the immune-related shortfalls of AAV - May 3, 2022
Bay Area INNO:
Chameleon Biosciences is developing a better way to treat rare genetic diseases
- Apr 25, 2022
CEO/CFO Magazine:
Expanding AAV Gene Therapies with EVADER™ - Mar-Apr 2022
Bay Area INNO:
Inno Madness
Apr 20, Apr 14, Apr 6, Mar 30, Mar 29, Mar 1 - Apr 14, 2022
BioSpace:
CureDuchenne is Filling the Therapeutic Pipeline with Next Generation DMD Treatments - Apr 14, 2022
eHealth Radio Network:
The Latest in Gene Therapy with Genine Winslow - Feb 15, 2022
BioSpace:
Chameleon's Cloaking Technology Makes Multi-Dose Gene Therapy a Reality - Feb 2, 2022
Bizwomen: In Her Own Words:
Scientist Genine Winslow - Jan 5, 2022
BioWorld:
Appointments & Advancements
Chameleon Biosciences welcomes Paul Fitzpatrick, Ph.D.
We are very pleased to announce and welcome Paul Fitzpatrick to the Chameleon team as a Vice President of R&D. In this role, Paul will be responsible for leading Chameleon’s research team in the further development of our EVADER™ platform technology, developing our pipeline programs and facilitating collaborations.
> Read More
Featured in BizWomen: Scientist Genine Winslow values having the right team
Before the COVID pandemic began, Genine Winslow and her team were already dealing in matters of illness and health. Learn about what inspired her to launch Chameleon Biosciences, the challenges that have arisen during the pandemic, and how she and her team are overcoming them and continuing to make progress toward life-changing gene therapies. Read the article—In Her Own Words:…
> Read More
Silicon Valley Scientist and Entrepreneur, Dr. Thomas Chalberg, Joins as Newest Board Appointee
Thomas W. Chalberg, PhD, a scientist, entrepreneur, and executive in Silicon Valley has joined Chameleon’s Board of Directors. We look forward to working with Dr. Chalberg who has spent the past 15 years developing novel therapies and life-changing products.
> Read More
EVADER™ – stealth mode, next-generation AAV-based gene therapy vectors (published in BioPharma Dealmakers)
Chameleon Biosciences is developing next-generation adeno-associated virus vectors that elicit minimal immune responses, allowing repeat dosing and resulting in superior efficacies. These EVADER vectors have universal application for existing adeno-associated virus vectors, and Chameleon is seeking partners to advance its lead program in severe hemophilia B and to programs that target retinal cells.
> Read More
Chameleon Presents at Solebury Trout Fall Private Company Showcase 2021
Genine Winslow, CEO and Founder of Chameleon Biosciences, was invited to present at the 8th Annual Virtual Solebury Trout Fall Private Company Showcase. This selective, annual showcase highlights new and emerging biotechs. Ms. Winslow shared exciting preclinical data on Chameleon’s proprietary next generation AAV-based vectors which are designed to overcome the immune response related challenges of current AAV gene therapies. See the slides and more.
> Read More
Chameleon Biosciences at CureDuchenne’s National “FUTURES” Conference
Genine Winslow, CEO and Founder of Chameleon Biosciences will be participating in a panel discussion at the upcoming CureDuchenne’s National “FUTURES” Conference.
> Read More